Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)
Mr. Burns' live presentation will not be web cast, but will be availablethrough the Company's web site at www.entremed.com.
Advertisement
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developingtherapeutic candidates primarily for the treatment of cancer and inflammation.MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is anoral cell-cycle regulator with activity against the mTOR pathway. Panzem(R)(2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncologypatients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1studies in advanced cancers. The Company has approved IND applications forPanzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, for cancer. EntreMed's goal is to develop andcommercialize new compounds based on the Company's expertise in angiogenesis,cell-cycle regulation and inflammation - processes vital to the treatment ofcancer and other diseases, such as rheumatoid arthritis. Additionalinformation about EntreMed is available on the Company's web site atwww.entremed.com and in various filings with the Securities and ExchangeCommission.CONTACT: Ginny Dunn Associate Director Corporate Communications & Investor Relations EntreMed, Inc. 240-864-2643
SOURCE EntreMed, Inc.